Clinical Trials List
Protocol Number306246
Not yet recruiting
2026-03-01 - 2028-10-31
Phase III
ICD-10K74.4
Secondary biliary cirrhosis
ICD-10K75.81
Nonalcoholic steatohepatitis (NASH)
ICD-10K76.0
Fatty (change of) liver, not elsewhere classified
ICD-10K76.89
Other specified diseases of liver
ICD-10R16.2
Hepatomegaly with splenomegaly, not elsewhere classified
ICD-9571.8
Other chronic nonalcoholic liver disease
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/03/01
Investigators and Locations
Co-Principal Investigator
- 歐信佑 Division of Radiology
- 洪肇宏 Digestive System Department
- 沈峰志 Division of Endocrinology
- 顏毅豪 Digestive System Department
- 常景棣 Division of Radiology
- 黃寳源 Digestive System Department
- 梁志明 Digestive System Department
- 蔡明釗 Digestive System Department
- 紀廣明 Digestive System Department
- 林麗珊 Division of Endocrinology
- 蔡嘉仁 Division of Endocrinology
- 陳建宏 Digestive System Department
- 吳鎮琨 Digestive System Department
- 張國欽 Digestive System Department
- 陳榮福 Division of Endocrinology
- Jing-Houng Wang Digestive System Department
Co-Principal Investigator
- 葉欣榮 Digestive System Department
- Tiong Cheng Digestive System Department
- 陳文昭 Digestive System Department
- Chun-Chao Chang Digestive System Department
Co-Principal Investigator
- 楊宏志 Division of General Internal Medicine
- 蘇東弘 Division of General Internal Medicine
- Shih-Jer Hsu Division of General Internal Medicine
- 嚴光晨 Division of Radiology
- Jia-Horng Kao 醫學研究部
- 曾岱宗 醫學研究部
Co-Principal Investigator
- 王志文 Digestive System Department
- Wan-Long Chuang Digestive System Department
- Jee-Fu Huang Digestive System Department
- 梁博程 Digestive System Department
- Chung-Feng Huang Digestive System Department
- Ming-Lun Yeh Digestive System Department
- Chia-Yen Dai Digestive System Department
Co-Principal Investigator
- 許銘澤 Digestive System Department
Co-Principal Investigator
- 邱彥程 Digestive System Department
- 簡世杰 Digestive System Department
- Chiu Hung Chiu Digestive System Department
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
16 participants
-
Global
1200 participants